Averin Capital Acquisition Corp. 8-K

What Happened
Averin Capital Acquisition Corp. announced on May 28, 2026 that the board appointed Akiko Moni Miyashita as a director, effective immediately. Ms. Miyashita, age 70, will serve as a member of the first class of directors, with her term expiring at the Company’s first annual general meeting. In connection with her appointment she signed joinders to the Company’s February 18, 2026 Letter Agreement (including waivers of certain redemption rights and an agreement to vote shares in favor of an initial business combination) and to the Registration Rights Agreement, and she entered into the Company’s standard director indemnity agreement.

Key Details

• Appointment date: May 28, 2026; term expires at the Company’s first annual general meeting.
• Background: Founder of Beacon Hill Strategy Group (since Oct 2024); previously EVP & Chief Strategy Officer at Valo Health (May 2019–Sep 2024) and a Halozyme Therapeutics board member (May 2022–May 2026). Over 25 years in strategy, finance and corporate development, with healthcare, life sciences, technology and AI experience.
• Governance/agreements: Signed joinder to Letter Agreement dated Feb 18, 2026 (waived certain redemption rights and agreed to vote shares for an initial business combination) and joinder to the Registration Rights Agreement; also signed the Company’s standard director indemnity agreement.
• No family relationships with other officers/directors and no reportable related-party transactions under Item 404(a) of Regulation S‑K.

Why It Matters
This adds an experienced strategy and life‑sciences executive to Averin’s board, bringing expertise in healthcare, AI-enabled drug discovery, M&A and corporate strategy—areas relevant to a SPAC pursuing an initial business combination. The joinder to the Letter Agreement (waiving certain redemption rights and committing to vote for a business combination) may affect shareholder redemption dynamics and support for a proposed transaction. Registration rights and the indemnity agreement are standard investor and director protections disclosed in the filing.